A common β1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to β-blockade

被引:131
作者
Sofowora, GG [1 ]
Dishy, V [1 ]
Muszkat, M [1 ]
Xie, HG [1 ]
Kim, RB [1 ]
Harris, PA [1 ]
Prasad, HC [1 ]
Byrne, DW [1 ]
Nair, UB [1 ]
Wood, AJJ [1 ]
Stein, CM [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37232 USA
关键词
D O I
10.1016/S0009-9236(02)17734-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background. A common polymorphism of the beta(1)-adrenergic receptor Arg389Gly markedly affects function in vitro, but little is known about its in vivo significance. Methods and Results: Resting and exercise hemodynamic responses were measured in subjects homozygous for Arg389 (n = 21) or Gly389 (n = 13) alleles before and 3 hours after administration of a beta-blocker, atenolol. Demographic characteristics and atenolol concentrations were similar in the two genotypic groups. Genotype had a marked effect on resting hemodynamic responses to atenolol, with Arg389-homozygous subjects having a larger decrease in resting systolic blood pressure (8.7 +/- 1.3 mm Hg versus 0.2 +/- 1.7 mm Hg, P < .001) and mean arterial blood pressure (7.2 +/- 1.0 mm Hg versus 2.0 1.7 mm Hg, P = .009). Attenuation of exercise-induced hemodynamic responses by atenolol was not affected by genotype. Conclusions. There is reduced sensitivity of Gly389 homozygotes to a beta-adrenergic receptor antagonist, and this polymorphism may be an important determinant of variability in response to P-blockade.
引用
收藏
页码:366 / 371
页数:6
相关论文
共 24 条
[1]   Polymorphism in the β1-adrenergic receptor gene and hypertension [J].
Bengtsson, K ;
Melander, O ;
Orho-Melander, M ;
Lindblad, U ;
Ranstam, J ;
Råstam, L ;
Groop, L .
CIRCULATION, 2001, 104 (02) :187-190
[2]  
BROWN HC, 1976, CLIN PHARMACOL THER, V20, P524
[3]   In-vivo studies do not support a major functional role for the Gly389Arg β1-adrenoceptor polymorphism in humans [J].
Büscher, R ;
Belger, H ;
Eilmes, KJ ;
Tellkamp, R ;
Radke, J ;
Dhein, S ;
Hoyer, PF ;
Michel, MC ;
Insel, PA ;
Brodde, OE .
PHARMACOGENETICS, 2001, 11 (03) :199-205
[4]   Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol [J].
Czendlik, CH ;
Sioufi, A ;
Preiswerk, G ;
Howald, H .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (06) :451-459
[5]  
Eichhorn E, 2001, NEW ENGL J MED, V344, P1659
[6]  
EISENHOFER G, 1986, CLIN CHEM, V32, P2030
[7]   CLONING OF THE CDNA FOR THE HUMAN BETA-1-ADRENERGIC RECEPTOR [J].
FRIELLE, T ;
COLLINS, S ;
DANIEL, KW ;
CARON, MG ;
LEFKOWITZ, RJ ;
KOBILKA, BK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (22) :7920-7924
[8]   Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction [J].
Gottlieb, SS ;
McCarter, RJ ;
Vogel, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (08) :489-497
[9]   Effects of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischemia [J].
Humma, LM ;
Puckett, BJ ;
Richardson, HE ;
Terra, SG ;
Andrisin, TE ;
Lejeune, BL ;
Wallace, MR ;
Lewis, JF ;
McNamara, DM ;
Picoult-Newberg, L ;
Pepine, CJ ;
Johnson, JA .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (09) :1034-+
[10]   DIRECT ENANTIOSPECIFIC HPLC BIOANALYSIS OF (R,S)-ATENOLOL ON A CHIRAL STATIONARY-PHASE [J].
KOFAHL, B ;
HENKE, D ;
MUTSCHLER, E .
CHIRALITY, 1993, 5 (06) :479-482